Glucotrack, Inc. current report, 02 August 2017

SEC Filing Summary: Integrity Applications, Inc. (Form 8-K)

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Integrity Applications, Inc. on August 2, 2017, reporting events occurring on July 31, 2017. The filing details the twelfth closing of a private placement offering of securities to accredited investors. The company is incorporated in Delaware and maintains its principal executive offices in Ashdod, Israel.

Key Financial Metrics and Transaction Details

  • Gross Proceeds: The Company received $1,000,000 in aggregate gross proceeds from the sale of 1,000 Units in this closing.
  • Securities Issued: Each Unit consists of one share of Series C 5.5% Convertible Preferred Stock and two warrants (Series C-1 and Series C-2).
  • Conversion Terms: The Preferred Stock is convertible into an aggregate of 222,236 shares of Common Stock at an initial conversion price of $4.50 per share.
  • Warrant Terms:
    • Series C-1 Warrants: Exercise price of $4.50 per share; exercisable for 100% of shares issuable upon conversion.
    • Series C-2 Warrants: Exercise price of $7.75 per share; exercisable for 100% of shares issuable upon conversion.
    • Total Warrant Coverage: The Warrants in this closing are exercisable for an aggregate of 444,472 shares of Common Stock.
  • Placement Agent Compensation: The Company paid a commission equal to 10% of the aggregate sales price (in cash and Common Stock) plus a 3% non-accountable expense allowance. Additionally, the Placement Agent received warrants to purchase up to 44,445 shares at $4.50 and 22,223 shares at $7.75.

Note: This filing does not provide specific data on the Company's overall revenue, net profit, operating cash flow, total debt, or liquidity position as of the reporting date.

Material Changes and Prior Issuances

This transaction represents the twelfth closing of an ongoing offering. The terms of the Preferred Stock and Warrants are identical to those issued in eleven prior closings between April 2016 and June 2017. The prior issuances involved the sale of an aggregate of 10,003.9 Units. No material changes to the terms of the offering were disclosed in this specific closing compared to the prior 8-K filings.

Guidance, Outlook, and Risks

The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the securities were sold without registration under the Securities Act of 1933 in reliance on Section 4(a)(2) exemptions. The offering was not subject to general solicitation and was limited to accredited investors.

Key Facts for Investor Verification

  • Verify the total number of Units issued across all twelve closings to assess total dilution potential.
  • Confirm the current cash balance and burn rate to determine if the $1,000,000 proceeds are sufficient for near-term operations.
  • Review the full terms of the "full ratchet anti-dilution protection" granted to the Placement Agent warrants, as this may impact future equity value.
  • Check subsequent filings for the actual conversion of Preferred Stock or exercise of Warrants.
  • Validate the use of proceeds as described in the press release (Exhibit 99.1) referenced in the filing.